Arşiv logosu
  • English
  • Türkçe
  • Giriş
    Yeni kullanıcı mısınız? Kayıt için tıklayın. Şifrenizi mi unuttunuz?
Arşiv logosu
  • Koleksiyonlar
  • Sistem İçeriği
  • Analiz
  • Talep/Soru
  • English
  • Türkçe
  • Giriş
    Yeni kullanıcı mısınız? Kayıt için tıklayın. Şifrenizi mi unuttunuz?
  1. Ana Sayfa
  2. Yazara Göre Listele

Yazar "Kahveci, Gizem Bakir" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
Sayfa Başına Sonuç
Sıralama seçenekleri
  • Küçük Resim Yok
    Öğe
    Compliance to levothyroxine treatment of the patients with hypothyroidism during SARS-CoV-2 pandemic era
    (Zaslavsky Publishing House, 2021) Bilgin, Satilmis; Meryem, Burcin; Tel, Atak; Duman, Tuba Taslamacioglu; Kurtkulagi, Ozge; Kahveci, Gizem Bakir; Sagdic, Tugrul
    Background. Hypothyroidism requires treatment with levothyroxine (L-T4) to keep patients euthyroid. The rate of hospital admissions for chronic conditions decreased during COVID-19 era. We aimed to observe whether hospital admissions of the patients with hypothyroidism decreased during COVID-19 compared to the same time period in 2019. We also aimed to find out the rate of treatment compliance in subjects with hypothyroidism during pandemic era. Materials and methods. This cross-sectional study was performed on patients who applied to Internal Medicine Department of Abant Izzet Baysal University Hospital, and who received L-T4 replacement therapy due to hypothyroidism. 108 hypothyroidism patients were included in the study with their consent forms. The patients were divided into 2 groups according to the treatment compliance; either as compliant or incompliant patients. Results. The last TSH level of compliant group was significantly lower than incompliant group (p < 0.001). The last fT4 level of the compliant group was significantly higher than that of the incompliant group (p = 0.04). The median of the LT-4 treatment used irregularly was 35 (10–90) days in incompliant group and was 0 (0–0) days in compliant group (p < 0.001). The number of irregularly L-T4 used days was significantly positively correlated with last TSH value (r = 0.564, p < 0.001), and negatively correlated with last FT4 value (r = –0.492, p < 0.001). Mean corpuscular volume (MCV) of the compliant and incompliant groups were 85 (69.1–97.5) fL and 89 (66–96.6) fL, respectively (p = 0.03). Retrospective nature and relatively small study population are two main limitations of our study. Conclusions. Compliance to treatment is very important to achieve euthyroid hormone levels in patients with hypothyroidism during COVID-19 pandemic. Elevated MCV levels could predict incompliance to treatment in hypothyroidism. © 2021. The Authors.
  • Yükleniyor...
    Küçük Resim
    Öğe
    Millennium pandemic: A Review of coronavirus disease (COVID-19)
    (2020) Bilgin, Satılmış; Kurtkulağı, Özge; Kahveci, Gizem Bakir; Duman, Tuba T.; Tel, Burçin Meryem Atak
    Coronaviruses, a large family of single-stranded RNA viruses, can infect humans and animals, and can cause neurological, gastrointestinal and hepatic diseases as well as causing various lung diseases, including pneumonia, with shortness of breath, cough and fever. At the end of December 2019, a group of health authorities reported unidentified cases of pneumonia in a seafood market in Wuhan, China. The World Health Organization (WHO) used term 2019 novel coronavirus (COVID-19) to refer to a coronavirus that affected the lower respiratory tract of patients with pneumonia in Wuhan, China on 29 December and the WHO announced that the official name of the 2019 novel coronavirus was coronavirus disease (COVID-19). COVID-19 is seen in many countries around the World and has been accepted as a pandemic by WHO. It is defined as a suspicious case with fever, sore throat, cough, and people with a history of traveling to China or some parts of the country, or someone who contact with a patient who has a history of travel in China or contact with a confirmed COVID-19 infection patient. Currently, there is no proven vaccine or antiviral therapy that can be used against animal or human coronavirus. To control the outbreak, the drugs must be developed as soon as possible. Various drugs have been used in the treatment of COVID-19 and the main ones are chloroquine, remdesivir, lopinavir/ritonavir, oseltamivir, favipiravir. Since the virus affects the whole World, vaccines and/or new curative antiviral drugs are needed to end the pandemic. For this purpose, large-scale observational studies are needed.

| Bolu Abant İzzet Baysal Üniversitesi | Kütüphane | Rehber | OAI-PMH |

Bu site Creative Commons Alıntı-Gayri Ticari-Türetilemez 4.0 Uluslararası Lisansı ile korunmaktadır.


Bolu Abant İzzet Baysal Üniversitesi Kütüphanesi, Bolu, TÜRKİYE
İçerikte herhangi bir hata görürseniz lütfen bize bildirin

DSpace 7.6.1, Powered by İdeal DSpace

DSpace yazılımı telif hakkı © 2002-2025 LYRASIS

  • Çerez Ayarları
  • Gizlilik Politikası
  • Son Kullanıcı Sözleşmesi
  • Geri Bildirim